Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease

Pauline Meij, Marcel B H J Vervoort, Elisabeth Bloemena, Tabitha E. Schouten, Cindy Schwartz, Seymour Grufferman, Richard F Ambinder, Jaap M. Middeldorp

Research output: Contribution to journalArticle

Abstract

A large group of juvenile Hodgkin's disease patients (n=242, mean age 11.7 years, 75% [n=181] seropositive) was evaluated for anti-Epstein-Barr virus (EBV) antibody responses and the presence of EBV-encoded EBER-RNA and latent membrane protein-1 (LMP1)-protein expression in the tumor. The molecular diversity of anti-EBV antibody responses in Hodgkin's disease patients with EBV-positive and-negative tumors was studied by enzyme-linked immunosorbent assay (ELISA) and immunoblot. Using purified recombinant LMP1 protein as antigen, the presence of antibodies to LMP1 was related to expression of LMP1 in the tumor cells and specific EBV-serological patterns. Antibodies to LMP1 were detected in 30% of the EBV-seropositive Hodgkin's disease patients. The presence of antibodies to LMP1 was not associated with a distinct anti-EBV antibody diversity profile (ELISA), but a significantly higher percentage of patients with antibodies to LMP1 had antibodies to ZEBRA and viral capsid antigen (VCA)-p18 (Immunoblot). Significantly more patients with an EBV-positive tumor had detectable antibody responses to LMP1, but the presence of antibodies to LMP1 did not reflect the expression of LMP1 protein in the tumor cells. Interestingly, all patients with the strongest antibody responses to LMP1 had EBV-negative tumors, suggesting immunological selection in vivo.

Original languageEnglish (US)
Pages (from-to)370-377
Number of pages8
JournalJournal of Medical Virology
Volume68
Issue number3
DOIs
StatePublished - Nov 1 2002

Fingerprint

Hodgkin Disease
Antibody Formation
Membrane Proteins
Human Herpesvirus 4
Antibodies
Neoplasms
Antibody Diversity
Enzyme-Linked Immunosorbent Assay
Epstein-Barr virus EBV-associated membrane antigen
Proteins
Viral Antigens
Capsid
RNA
Antigens

Keywords

  • EBV
  • Immunity
  • Immunological selection
  • Oncogenesis
  • Serology

ASJC Scopus subject areas

  • Virology

Cite this

Meij, P., Vervoort, M. B. H. J., Bloemena, E., Schouten, T. E., Schwartz, C., Grufferman, S., ... Middeldorp, J. M. (2002). Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. Journal of Medical Virology, 68(3), 370-377. https://doi.org/10.1002/jmv.10213

Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. / Meij, Pauline; Vervoort, Marcel B H J; Bloemena, Elisabeth; Schouten, Tabitha E.; Schwartz, Cindy; Grufferman, Seymour; Ambinder, Richard F; Middeldorp, Jaap M.

In: Journal of Medical Virology, Vol. 68, No. 3, 01.11.2002, p. 370-377.

Research output: Contribution to journalArticle

Meij, Pauline ; Vervoort, Marcel B H J ; Bloemena, Elisabeth ; Schouten, Tabitha E. ; Schwartz, Cindy ; Grufferman, Seymour ; Ambinder, Richard F ; Middeldorp, Jaap M. / Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. In: Journal of Medical Virology. 2002 ; Vol. 68, No. 3. pp. 370-377.
@article{2dea621c31c34f3ab69a62f14eb68958,
title = "Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease",
abstract = "A large group of juvenile Hodgkin's disease patients (n=242, mean age 11.7 years, 75{\%} [n=181] seropositive) was evaluated for anti-Epstein-Barr virus (EBV) antibody responses and the presence of EBV-encoded EBER-RNA and latent membrane protein-1 (LMP1)-protein expression in the tumor. The molecular diversity of anti-EBV antibody responses in Hodgkin's disease patients with EBV-positive and-negative tumors was studied by enzyme-linked immunosorbent assay (ELISA) and immunoblot. Using purified recombinant LMP1 protein as antigen, the presence of antibodies to LMP1 was related to expression of LMP1 in the tumor cells and specific EBV-serological patterns. Antibodies to LMP1 were detected in 30{\%} of the EBV-seropositive Hodgkin's disease patients. The presence of antibodies to LMP1 was not associated with a distinct anti-EBV antibody diversity profile (ELISA), but a significantly higher percentage of patients with antibodies to LMP1 had antibodies to ZEBRA and viral capsid antigen (VCA)-p18 (Immunoblot). Significantly more patients with an EBV-positive tumor had detectable antibody responses to LMP1, but the presence of antibodies to LMP1 did not reflect the expression of LMP1 protein in the tumor cells. Interestingly, all patients with the strongest antibody responses to LMP1 had EBV-negative tumors, suggesting immunological selection in vivo.",
keywords = "EBV, Immunity, Immunological selection, Oncogenesis, Serology",
author = "Pauline Meij and Vervoort, {Marcel B H J} and Elisabeth Bloemena and Schouten, {Tabitha E.} and Cindy Schwartz and Seymour Grufferman and Ambinder, {Richard F} and Middeldorp, {Jaap M.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1002/jmv.10213",
language = "English (US)",
volume = "68",
pages = "370--377",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease

AU - Meij, Pauline

AU - Vervoort, Marcel B H J

AU - Bloemena, Elisabeth

AU - Schouten, Tabitha E.

AU - Schwartz, Cindy

AU - Grufferman, Seymour

AU - Ambinder, Richard F

AU - Middeldorp, Jaap M.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - A large group of juvenile Hodgkin's disease patients (n=242, mean age 11.7 years, 75% [n=181] seropositive) was evaluated for anti-Epstein-Barr virus (EBV) antibody responses and the presence of EBV-encoded EBER-RNA and latent membrane protein-1 (LMP1)-protein expression in the tumor. The molecular diversity of anti-EBV antibody responses in Hodgkin's disease patients with EBV-positive and-negative tumors was studied by enzyme-linked immunosorbent assay (ELISA) and immunoblot. Using purified recombinant LMP1 protein as antigen, the presence of antibodies to LMP1 was related to expression of LMP1 in the tumor cells and specific EBV-serological patterns. Antibodies to LMP1 were detected in 30% of the EBV-seropositive Hodgkin's disease patients. The presence of antibodies to LMP1 was not associated with a distinct anti-EBV antibody diversity profile (ELISA), but a significantly higher percentage of patients with antibodies to LMP1 had antibodies to ZEBRA and viral capsid antigen (VCA)-p18 (Immunoblot). Significantly more patients with an EBV-positive tumor had detectable antibody responses to LMP1, but the presence of antibodies to LMP1 did not reflect the expression of LMP1 protein in the tumor cells. Interestingly, all patients with the strongest antibody responses to LMP1 had EBV-negative tumors, suggesting immunological selection in vivo.

AB - A large group of juvenile Hodgkin's disease patients (n=242, mean age 11.7 years, 75% [n=181] seropositive) was evaluated for anti-Epstein-Barr virus (EBV) antibody responses and the presence of EBV-encoded EBER-RNA and latent membrane protein-1 (LMP1)-protein expression in the tumor. The molecular diversity of anti-EBV antibody responses in Hodgkin's disease patients with EBV-positive and-negative tumors was studied by enzyme-linked immunosorbent assay (ELISA) and immunoblot. Using purified recombinant LMP1 protein as antigen, the presence of antibodies to LMP1 was related to expression of LMP1 in the tumor cells and specific EBV-serological patterns. Antibodies to LMP1 were detected in 30% of the EBV-seropositive Hodgkin's disease patients. The presence of antibodies to LMP1 was not associated with a distinct anti-EBV antibody diversity profile (ELISA), but a significantly higher percentage of patients with antibodies to LMP1 had antibodies to ZEBRA and viral capsid antigen (VCA)-p18 (Immunoblot). Significantly more patients with an EBV-positive tumor had detectable antibody responses to LMP1, but the presence of antibodies to LMP1 did not reflect the expression of LMP1 protein in the tumor cells. Interestingly, all patients with the strongest antibody responses to LMP1 had EBV-negative tumors, suggesting immunological selection in vivo.

KW - EBV

KW - Immunity

KW - Immunological selection

KW - Oncogenesis

KW - Serology

UR - http://www.scopus.com/inward/record.url?scp=0036836520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036836520&partnerID=8YFLogxK

U2 - 10.1002/jmv.10213

DO - 10.1002/jmv.10213

M3 - Article

C2 - 12226824

AN - SCOPUS:0036836520

VL - 68

SP - 370

EP - 377

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 3

ER -